ANAPTYSBIO Form 144 Filed
AnaptysBio insider files form 144, indicating potential stock sale. May impact stock price.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.
Related stories
Afaq Holding Reports Q3 Revenue of 17 Million Dinars
M impact | EQUITY | Oct 29, 2026, 02:42 PM UTC
Afaq Holding reports Q3 loss of 328,057 dinars
M impact | EQUITY | Oct 29, 2026, 02:41 PM UTC
Teladoc Health Reports Q3 Revenue of $605.1M, Loss Narrows
Third-quarter revenue fell 3.4% year over year to $605.1 million. Net loss narrowed to $26.93 million from $49.51 million, while diluted loss per share was $0.15 versus $0.28 a yea
M impact | EQUITY | Oct 29, 2026, 02:41 PM UTC
Klabin Sees El Niño Pressuring Operations Through Q1 2027
Klabin sees El Niño pressuring its operations through the first quarter of 2027.
L impact | EQUITY | Oct 29, 2026, 02:41 PM UTC
Garrett Motion shares rise 5.2% after Q3 earnings
Garrett Motion shares rose 5.2% in Thursday trading after the company reported Q3 earnings and higher net sales.
M impact | EQUITY | Oct 29, 2026, 02:40 PM UTC
Nextensa Sells Luxembourg Office Building for EUR43.5 Million
Nextensa announced the sale of a Luxembourg office building to Centre Hospitalier de Luxembourg for EUR43.5 million.
L impact | EQUITY | Oct 29, 2026, 02:40 PM UTC